Pricing Log in Create free account
Friday 6 November 2026 Export IOVA’s income statement to Excel — free account

Iovance Biotherapeutics, Inc.

IOVA Healthcare Biotechnology

Iovance Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $263.5 million, up 60.6% from fiscal 2024.

Revenue
+80.1%
EPS
+80.0%
Free cash flow
+89.7%

Quarter to September 2026, against a year earlier

7.99 0.25 +3.23%
Market cap
$3.5B
P/E
0.0×
Fwd P/E
−18.9×
Dividend yield
—
F-score
4/9
Altman Z
−2.30
Beneish M
−2.46
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Iovance Biotherapeutics, Inc. (IOVA) Revenue

Alert me on Revenue

Iovance Biotherapeutics, Inc.'s revenue for fiscal 2025 was $263.5M, up 60.6% from $164.1M in fiscal 2024. Over the twelve months to 30 September 2026 it was $379.0M. Iovance Biotherapeutics, Inc. ranks 50th of 390 Biotechnology companies by revenue.

Revenue, annual

Embed this chart

Annual newest first

Period Revenue Change
FY2025 $263.5M 60.60%
FY2024 $164.1M 13,698.99%
FY2023 $1.2M —

Quarterly newest first

Period Revenue Change
Sep 2026 $121.5M 22.31%
Jun 2026 $99.3M 39.04%
Mar 2026 $71.4M (17.68%)
Dec 2025 $86.8M 28.64%
10 more quarters

Revenue against peers

Company Revenue
ACAD ACADIA Pharmaceuticals Inc. compare $1.2B
IOVA Iovance Biotherapeutics, Inc. $379.0M
ABCL AbCellera Biologics Inc. compare $66.2M
TNGX Tango Therapeutics, Inc. compare $62.4M
XENE Xenon Pharmaceuticals Inc. compare $16.9M
RLAY Relay Therapeutics, Inc. compare $11.0M
PBLS Parabilis Medicines, Inc. compare —
EWTX Edgewise Therapeutics, Inc. compare —
IRON Disc Medicine, Inc. compare —

What Revenue is

Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.

Reported line item

The full definition of Revenue →

More on IOVA